25,684 Shares in Laboratory Co. of America Holdings (NYSE:LH) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new stake in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 25,684 shares of the medical research company's stock, valued at approximately $5,838,000.

Several other institutional investors also recently bought and sold shares of the business. Mendota Financial Group LLC bought a new position in shares of Laboratory Co. of America during the 4th quarter worth approximately $29,000. Provence Wealth Management Group acquired a new position in Laboratory Co. of America during the 3rd quarter valued at about $29,000. Tradewinds Capital Management LLC purchased a new stake in Laboratory Co. of America in the third quarter valued at about $34,000. Bruce G. Allen Investments LLC acquired a new stake in Laboratory Co. of America in the fourth quarter valued at approximately $60,000. Finally, Planned Solutions Inc. purchased a new stake in shares of Laboratory Co. of America in the fourth quarter valued at approximately $76,000. 95.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on LH shares. Leerink Partnrs reissued an "outperform" rating on shares of Laboratory Co. of America in a research note on Monday, February 26th. Truist Financial decreased their target price on Laboratory Co. of America from $270.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, April 26th. Barclays reduced their price objective on Laboratory Co. of America from $234.00 to $213.00 and set an "equal weight" rating for the company in a research note on Friday, April 26th. Evercore ISI assumed coverage on shares of Laboratory Co. of America in a research note on Friday, February 9th. They set an "in-line" rating and a $240.00 target price on the stock. Finally, TheStreet downgraded shares of Laboratory Co. of America from a "b-" rating to a "c+" rating in a research note on Thursday, February 15th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $243.14.

Laboratory Co. of America Stock Up 0.1 %

Shares of NYSE:LH traded up $0.11 during trading on Wednesday, hitting $201.61. 556,886 shares of the company were exchanged, compared to its average volume of 760,338. The firm's 50 day moving average price is $209.55 and its 200-day moving average price is $214.89. Laboratory Co. of America Holdings has a 12-month low of $174.20 and a 12-month high of $234.09. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.88 and a quick ratio of 0.76. The stock has a market capitalization of $17.00 billion, a P/E ratio of 40.57, a PEG ratio of 1.51 and a beta of 1.02.

Laboratory Co. of America (NYSE:LH - Get Free Report) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, topping the consensus estimate of $3.48 by $0.20. The company had revenue of $3.18 billion for the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The firm's revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.82 earnings per share. On average, research analysts predict that Laboratory Co. of America Holdings will post 14.87 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.43%. The ex-dividend date of this dividend is Tuesday, May 28th. Laboratory Co. of America's dividend payout ratio is presently 57.95%.

Insiders Place Their Bets

In other Laboratory Co. of America news, CFO Glenn A. Eisenberg sold 34,504 shares of the company's stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $215.97, for a total transaction of $7,451,828.88. Following the completion of the transaction, the chief financial officer now owns 23,595 shares in the company, valued at approximately $5,095,812.15. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Glenn A. Eisenberg sold 34,504 shares of the company's stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $215.97, for a total value of $7,451,828.88. Following the sale, the chief financial officer now owns 23,595 shares of the company's stock, valued at approximately $5,095,812.15. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Der Vaart Sandra D. Van sold 237 shares of the business's stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $226.45, for a total value of $53,668.65. Following the completion of the transaction, the executive vice president now directly owns 7,637 shares of the company's stock, valued at $1,729,398.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,244 shares of company stock valued at $12,360,478. 0.85% of the stock is owned by company insiders.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).